The Medicare demonstration that caps beneficiaries’ monthly insulin costs might be a model to consider for other highly rebated drugs that treat chronic conditions, if Congress fails to overhaul Part D, a congressional Medicare adviser said Friday (Jan. 14). The demo is viewed as a back-door way to share drug rebates at the point of sale. The Trump CMS created the Part D Senior Savings demonstration that caps monthly insulin copays at $35, which applies during the deductible, initial coverage...